



References

1. Copplesstone JA, Smith AG, Oscier DG, et al. True outlook in acute myeloblastic leukemia. Lancet 1986; 1:1104
2. Levine AS, Graw RG Jr, Young RC. Management of infections in patients with leukemia and lymphoma: current concepts and experimental approaches[Review]. Seminars in Hematology 1972; 9(2):141-79
3. Bodey GP, Rodriguez V, Chang H-Y, Narboni G. Fever and infections in leukemic patients. A study of 494 consecutive patients. Cancer 1978; 41:1610-1622
4. Chang H-Y, Rodriguez V, Narboni G, Bodey GP, Luna MA, Freireich EJ. Causes of death in adults with acute leukemia. Medicine (Baltimore) 1976; 55:259-268
5. Hughes WT, Armstrong D, Bodey GD, Feld R, Mandell GL, Meyers JD, et al. Guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. J Infect Dis 1990; 161:381-96
6. Slavin RE, Dias MA, Saral R. Cytosine arabinoside induced gastrointestinal toxic alterations in sequential chemotherapeutic protocols, a clinical-pathologic study of 33 patients. Cancer 1972; 42: 1747-1759
7. Schimpff SC. Infection prevention during profound granulocytopenia: new approaches to alimentary canal antimicrobial suppression. Ann Intern Med 1980; 93: 358-361

8. Pizzo PA, Robichaud KJ, Edwards BK, Schumaker C, Kramer BS, Johnson A. Oral antibiotic prophylaxis in patients with cancer. A double-blind randomized placebo-controlled trial. J Pediatr 1983; 102:125-133
9. Kovatch AL, Wald ER, Albo VC, Prin W, Orlando SJ, Wollman MR, Phebus CK, Shapiro ED. Oral trimethoprim/sulfamethoxazole for prevention of bacterial infection during the induction phase of cancer chemotherapy in children. Pediatrics 1985; 76:754-758
10. Cavallito CJ, Buck JS, Suter CM. Allicin, the antibacterial principle of *Allium sativum*. II. Determination of the chemical structure. J Am Chem Soc 1944; 66: 1952-1954
11. Chen XQ, Jin YY, editors. New Pharmacology. [Chinese] 13th edition. Beijing: People's Health Publication Company, 1992: 105
12. Chen HC, Chang MD, Chang TJ. Antibacterial properties of some spice plants before and after heat treatment. [Chinese] Chung-Hua Min Kuo Wei Sheng Wu Chi Mien i Hsuch Tsa Chih-Chinese Journal of Microbiology and Immunology 1985; 18(3): 190-195
13. Venugopal PV, Venugopal TV. Antidermatophytic activity of garlic (*Allium sativum*) in vitro. Int J of Dermatol 1995; 34(4):278-279
14. Guo NL, Lu DP, Woods GL, Reed E, Zhou GZ, Zhang LB, et al. Demonstration of the anti-viral activity of garlic extract against human cytomegalovirus in vitro. Chin Med J 1993; 106(2): 93-96

15. Chowdhury AK, Ahsan M, Islam SN, Ahmed ZU. Efficacy of aqueous extract of garlic and allicin in experimental shigellosis in rabbits. Indian Journal of Medical Research 1991; 93:33-36
16. Clasener HAL, Vollaard EJ, van Saene HKF. Long-term prophylaxis of infection by selective decontamination in leukopenia and in mechanical ventilation. Rev Infect Dis 1987; 9:295-328
17. Hughes WT, Kuhn S, Chaudhary S, Feldman S, Verzos M, Aur RT. Successful chemoprophylaxis for pneumocystic carinii pneumonitis. N Engl J Med 1977; 297(26): 1419-1426
18. Wade JC. Management of infection in patients with acute leukemia. Hematology/Oncology Clinics of North America 1993; 7(1): 294-315
19. Kern WV, Andriof E, Oethinger M, Kern P, Hacker J, Marre R. Emergence of fluoroquinolone-resistant Escherichia coli at a cancer center. Antimicrobial Agents & Chemotherapy 1994; 38(4): 681-687
20. Khan MB, Bhat DA, Navalkar RG. Inhibition of Mycobacterium avium complex isolates from AIDS patients by garlic (Allium sativum). Jurnal of Antimicrobial Chemotherapy 1993; 32(4): 623-626
21. Jiang JY. Therapy of pulmonary fungal infection of cor pulmonale by garlic.[Chinese] Chung-Kuo Chung Hsi i Chieh Ho Tsa Chih 1991; 11(7):429
22. Liu WC. Treatment of pediatric pulmonary fungal infection by oral garlic extract. [Chinese] J of Appli Med 1986; (6): 6

23. Departments of Neurology and Traditional Chinese Medicine and Pharmacology of the First Affiliated Hospital and Department of Microbiology, Hunan Medical College, Changsha. Garlic in cryptococcal meningitis: A preliminary report of 21 cases. Chin Med J 1980; 93(2): 123-126
24. Zhang RS. A clinical study on allicin in the prevention of thrush in newborn infants. [Chinese] Chung-Kuo Chung Hsi i Chieh Ho Tsa Chih 1992; 12(1): 28-29
25. Lu DP, Guo NL, Jin NR, Zheng H, Lu XJ, Shi Q, et al. Allogeneic bone marrow transplantation for the treatment of leukemia. Chin Med J 1990; 103(2): 125-130
26. Guo QY. Garlic in treatment of AIDS: A report of 98 cases. [Chinese] Combined Clinical Medicine 1994; 10(3): 163
27. Lemeshow S, Hosmer DW Jr, Klar J, Lwanga SK. Adquacy of sample size in health studies. Chichester: John Wiley & Sons (on behalf of WHO), 1990
28. Yu XR, Cong YZ. The chemical composition and pharmacological activity of garlic. [Chinese] Chinese Traditional and Herbal Drugs 1994; 25(3): 158-160
29. Sui GL, Meng MJ, Shi L, Yuan L, Hu GS. A study on different preparations of garlic. [Chinese] Chinese Journal of Traditional Drugs 1996; 21(1): 32-33
30. De Jong PJ, de Jong MD, Kuijper EJ, van der Lelie H. The value of surveillance cultures in neutropenic patients receiving selective intestinal decontamination. Scandinavian Journal of Infectious Diseases 1993; 25(1): 107-113

31. Tan YJ. A analysis of the infection of 78 patients with hematological malignancies. [Chinese] Journal of Clinical Hematology 1994; 7(2): 65
32. Tan HJ, Tang SQ, Ran CR. Neutropenia and selection of antibiotics in acute leukemia. [Chinese] Journal of Clinical Pediatrics 1990; 8(6): 364
33. Feng M, Zhang GM, Jiang HY. Treatment of infection in patients with acute leukemia. [Chinese] Shanxi Leukemia 1994; 3(1): 45
34. Ward TT, Thomas RG, Fye CL, Arbeit R, Coltman CA, Craig WJ et al. Thimethoprim-sulfamethoxazole prophylaxis in granulocytopenic patients with acute leukemia: Evaluation of serum antibiotic levels in a randomized, double-blind, placebo-controlled department of veterans affairs cooperative study. Clinical Infectious Diseases 1993; 17:323-332
35. Jones GR, Konsler GK, Dunaway RP, Gold SH, Cooper HA, Wells RJ. Risk factors for recurrent fever after the discontinuation of empiric antibiotic therapy for fever and neutropenia in pediatric patients with a malignancy or hematologic condition. The Journal of Pediatrics 1994; 124(5): 703-708
36. de Marie S, van den Broek PJ, Willemze R, van Furth R. Strategy for antibiotic therapy in febrile neutropenic patients on selective antibiotic decontamination. Eur J Clin Microbiol Infect Dis 1993; 12: 897-906
37. Jackson SK, Parton J, Barnes RA, Poynton CH, Fegan C. Effect of IgM-enriched intravenous immunoglobulin (Pentaglobulin) on endotoxaemia and anti-endotoxin antibodies in bone marrow transplantation. Eur J Clin Invest 1993; 23:540-545

38. Bow EJ, Mandell LA, Louie TJ, Feld R, Palmer M, Zee B et al. Quinolone-based antibacterial chemoprophylaxis in neutropenic patients: Effect of augmented gram-positive activity on infectious morbidity. Annals of Internal Medicine 1996; 125(3): 183-190
39. Bow EJ, Loewen R, cheang MS, Schacter B. Invasive fungal disease in adults undergoing remission-induction therapy for acute myeloid leukemia: the pathogenetic role of the antileukemic regimen. Clinical Infectious Diseases 1995; 21(2): 361-369
40. Guiot HF, Fibbe WE, van't Wout JW. Risk factors for fungal infection in patients with malignant hematologic disorders: implicaitons for empirical therapy and prophylaxis. Clinical Infectious Diseases 1994; 18(4): 525-532
41. Salonen J, Nikoskelainen J. Lethal infections in patients with hematological malignancies. European Journal of Haematology 1993; 51(2): 102-108
42. Funai N, Shimamoto Y, Tokunaga O, Sugihara W, Yamaguchi M. Ten-year survey of incidence of infection as a cause of death in hematologic malignancies: study of 90 autopsied cases. Acta Haematologica 1995; 93(1): 25-30
43. Makheja AN, Bailey JM. Antiplatelet constituents of garlic and onion. Agents and Actions 1990; 29(3-4): 360-363
44. Kiesewetter H, Jung F, Pindur G, Jung EM, Mrowietz C, Wenzel E. Effect of garlic on thrombocyte aggregation, microcirculation, and other risk factors. International Journal of Clinical Pharmacology, therapy, & toxicology 1991; 29(4): 151-155

45. Kieseletter H, Jung F, Mrowietz C, Pindur G, Heiden M, Wenzel E et al. Effects of garlic on blood fluidity and fibrinolytic activity: a randomised, placebo-controlled, double-blind study. British Journal of Clinical Practice-symposium supplement. 1990; 69: 24-29
46. German K, Kumar U, Blackford HN. Garlic and the risk of TURP bleeding. British Journal of Urology 1995; 76(4): 518
47. Bow EJ, Rayner E, Louie TJ. Comparison of norfloxacin with cotrimoxazole for infection prophylaxis in acute leukemia. The American Journal of Medicine 1988; 84: 847-854
48. Liu L, Liu XC. Clinical analysis of the nosocomial infections of patients with leukemia. [Chinese] Leukemia 1996; 5(3): 164-165
49. Tan YX, Zheng HJ, Zhu H, Luo L, Wei YL. An analysis of the nosocomial infections in patients with acute leukemia. [Chinese] Chinese Journal of Hematology 1996; 17(1): 29-30
50. Bow EJ, Ronald AR. Editorial: Antibiotic chemoprophylaxis in neutropenic patients-where do we go from here [Editorial] Clinical Infectious Diseases 1993; 17: 333-337
51. Cruciani M, Rampazzo R, Malena M, Lazzarini L, Todeschini G, Messori A et al. Prophylaxis with fluoroquinolones for bacterial infections in neutropenic patients: a meta-analysis. Clinical Infectious diseases 1996; 23(4): 795-805
52. Silagy C, Neil A. Garlic as a lipid lowering agent--a meta-analysis. Journal of the Royal College of Physicians of London 1994; 28(1): 39-45

Appendix A

Data Collection Form

Code for fill-in blanks: 9 = missing, unknown or not performed, 8 = can't evaluate

Baseline data:

Code No _____ Name _____ Hospital No _____

- | | |
|--|---|
| 1. Code No _____ | 1. <input type="checkbox"/> <input type="checkbox"/> |
| 2. Hospital No _____ | 2. <input type="checkbox"/> <input type="checkbox"/> |
| 3. Age _____ (years) | 3. <input type="checkbox"/> <input type="checkbox"/> |
| 4. Sex <input type="checkbox"/> 1. M, <input type="checkbox"/> 2. F | 4. <input type="checkbox"/> <input type="checkbox"/> |
| 5. Duration of sickness _____ (days) | 5. <input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> |
| 6. FAB subtypes <input type="checkbox"/> 1.M1, <input type="checkbox"/> 2.M2, <input type="checkbox"/> 3.M3,
<input type="checkbox"/> 4.M4, <input type="checkbox"/> 5.M5, <input type="checkbox"/> 6. M6 | 6. <input type="checkbox"/> |
| 7. Performance status <input type="checkbox"/> 0, <input type="checkbox"/> 1, <input type="checkbox"/> 2, <input type="checkbox"/> 3, <input type="checkbox"/> 4 | 7. <input type="checkbox"/> |
| 8. Hemoglobin (g/L) | 8. <input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> |
| 9. WBC (X10 ⁹ /L) _____ | 9. <input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> . <input type="checkbox"/> <input type="checkbox"/> |
| 10. Platelets (X10 ⁹ /L) _____ | 10. <input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> |
| 11. Severe bone marrow suppression period _____ (days) | 11. <input type="checkbox"/> <input type="checkbox"/> |
| 12. Bone marrow recovery period _____ (days) | 12. <input type="checkbox"/> <input type="checkbox"/> |
| 13. Stratification: <input type="checkbox"/> 1. Newly diagnosed, <input type="checkbox"/> 2. Relapsed, <input type="checkbox"/> 3. Consolidation | 13. <input type="checkbox"/> |
| 14. Complete remission after induction <input type="checkbox"/> 1. Yes, <input type="checkbox"/> 2. No | 14. <input type="checkbox"/> |

Outcomes

Primary

15. 1. Infection, 2. Non-infection 15.

Secondary

16. Death 1. Yes, 2. No 16.
17. Causes of death 1. Infection, 2. Bleeding, 3. Others 17.
18. Total days of fever _____ 18.
19. Total days of antibiotics given _____ 19.
20. Types of antibiotics 20.
1. Aminoglycoside+anti-pseudomonal penicillin
2. Aminoglycoside+3rd generation cephalosporin
3. Aminoglycoside+imipenem/cilastatin
4. 3rd generation cephalosporine or imipenem/cilastatin alone
21. Numbers of antibiotic modification _____ 21.
22. Addition of antifungal drugs 1. Yes, 2. No 22.
23. Categories of infection 23.
1. Bacteremia, 2. Other bacterially documented
3. Clinically documented, 4. Unexplained fever
24. Nausea 1. Yes, 2. No 24.
25. Vomiting _____ 25.
26. Platelet transfusions _____ (units) 26.
27. Packed red blood cell transfusions _____ (units) 27.
28. No. of positive fungal cultures: Rectum _____ Oropharynx _____
29. Kind of fungi


Appendix B**ECOG Criteria for Estimation of Performance Status**

<u>Grade</u>	<u>Scales</u>
0	Fully active, able to carry on pre-disease performance without restriction
1	Ambulatory, but have symptoms
2	Ambulatory, confined to bed and chair less than 50% of waking hours
3	Capable of only limited self-care, confined to bed or chair more than 50% of waking hours
4	Completely disabled, can't carry on any self-care, totally confined to bed or chair

สถาบันวิทยบริการ
จุฬาลงกรณ์มหาวิทยาลัย

Appendix C

Antibiotic Guidelines



Appendix D**CONSENT FORM**

I have been informed that the Department of Hematology, First General Hospital of West China University of Medical Sciences is conducting a study on the prevention of infections of acute myelogenous leukemia patients. The purpose of this study is to evaluate whether oral ingestion of medical plant can prevent the patients from getting infected during this course of chemotherapy.

I agree to participate in this study and understand it will involve the following procedure:

1. General physical examination every day and whenever necessary.
2. Bacterial surveillance cultures once a week.
3. Proposed treatment for 28 days or shorter if my peripheral white blood cell count exceeds $2 \times 10^9/L$ within 28 days.
4. Routine treatment for acute myelogenous leukemia and other related conditions.

I am informed that the medicine I will be taking may work or may not work for the purpose of infection prophylaxis. I am also informed of the possible side effect of the medicine.

I understand that if I do not participate in the study, I will have the alternative of routine treatment for my disease.

I understand that my agreement of participation in this study is entirely voluntary and I may withdraw at any time without having to give any reason. The quality of my medical care will not be influenced by my refusal or withdrawal from the study.

My attending physician has already talked with me about the study and answered all my questions related to the study. I have been informed that I have the opportunity to ask more questions about this study and I can also contact the researchers in this hospital on Tel. ext. 23589.

Patient's name: _____ Date of signature: _____

Physician's name: _____



VITAE

Dr. Li Qin was born on January 15, 1963 in Xinjiang, P. R. China. She graduated from the School of Medicine, West China University of Medical Sciences, Chengdu, in 1986 after accomplishment of a six-year course and obtained an M.D.

After graduation, she completed 2 years of residency of general internal medicine in the Department of Internal Medicine, First General Hospital of West China University of Medical Sciences. Then she was enrolled in postgraduate study and obtained a master degree in hematology in 1991. After that she completed 2 years of fellowship and 1 year chief residency in the Department of Hematology, First General Hospital of West China University of Medical Sciences. She has been working as an attending physician of hematology since 1994. Since June, 1996, she has been admitted in the Master Degree Program of Health Development in Faculty of Medicine of Chulalongkorn University, Bangkok, Thailand. She was supported in this program by Thai CERTC (Clinical Epidemiology Regional Training Center) consortium of INCLIN (International Clinical Epidemiology Network), principally sponsored by Rockefeller Foundation, New York, USA.

Her principal interest in the medical field is research in hematology, especially in the infection of immuno-compromised patients. During this course, she has conducted a clinical controlled trial on the efficacy of garlic, a natural plant, on the prevention of infection of acute myelogenous leukemia patients during chemotherapy.

Presently, she is working as an attending physician in the Department of Hematology, First General Hospital of West China University of Medical Sciences. Her interest and the training she received in the field of clinical epidemiology also enable her to teach clinical epidemiology in the CEU of West China University of Medical Sciences, Chengdu.